Market Cap 480.67M
Revenue (ttm) 10.00M
Net Income (ttm) -130.64M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,306.40%
Debt to Equity Ratio 2.06
Volume 1,628,600
Avg Vol 2,269,624
Day's Range N/A - N/A
Shares Out 61.55M
Stochastic %K 33%
Beta 0.89
Analysts Strong Sell
Price Target $15.50

Company Profile

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 292 4200
Address:
117 Kendrick Street, Suite 500, Needham, United States
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 5:44 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $VSTM Current Share Price: $7.95 Contracts: $VSTM January 15, 2027 $10 Calls Scale in: $3.53- $4.32 Scale out: $5.49-$7.06 Can Easily Capture: 60% ROI Blended DTE: 447 Days | Join Elites here: https://liquidtheta.com
0 · Reply
dl42
dl42 Oct. 25 at 3:22 PM
$VSTM maybe it’s just me being optimistic but this reminds me of TGTX 3-4yrs ago. It just hung around below $10 even w a bunch of upcoming catalysts and then they all started to hit.
0 · Reply
Universaal
Universaal Oct. 25 at 2:15 AM
$VSTM we get another opportunity to load more under 7.90
0 · Reply
NIJO89
NIJO89 Oct. 24 at 11:36 PM
$VSTM Verastem Oncology (VSTM) - Q3 2025 Overview and Key Upcoming Q4 Catalysts: The second-quarter Form 10-Q (filed August 7, 2025) outlined multiple milestones expected in the second half of 2025. While Q3 will primarily reflect early U.S. launch revenue from AVMAPKI (avutometinib + defactinib), expected to land around US $6–8 million, and steady progress in the VS-7375 KRAS G12D program, four major updates remain pending for Q4 2025 that could significantly influence both sentiment and valuation.
0 · Reply
Sdcharger
Sdcharger Oct. 24 at 8:12 PM
$VSTM Short interest at: 10/15. 18.1 million 9/30. 17.5 million The shorts continue to press their bets and the stock continues to lag.
1 · Reply
Marketismanipulated2
Marketismanipulated2 Oct. 24 at 8:06 PM
$VSTM special place in hell for these thieving clock suckers!🤬🤬🤬
0 · Reply
SagehenNed
SagehenNed Oct. 24 at 7:48 PM
$VSTM classic late day VSTM fade.
1 · Reply
Marketismanipulated2
Marketismanipulated2 Oct. 24 at 7:33 PM
$VSTM thieves let it run up or down into the close? Guessing down since they have zero morals.
0 · Reply
Universaal
Universaal Oct. 24 at 4:54 PM
$PRQR few companies i never trust mgmt $PRQR $VSTM bcz these two never gives a fk about their investors I own both
0 · Reply
Universaal
Universaal Oct. 24 at 4:14 PM
$VSTM all I request Dan not to dilute anymore just get some investments from big biotech companies or cut your fking salaries
0 · Reply
Latest News on VSTM
Verastem Oncology to Present at Upcoming Investor Conferences

Aug 27, 2025, 7:00 AM EDT - 2 months ago

Verastem Oncology to Present at Upcoming Investor Conferences


Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 8:55 PM EDT - 2 months ago

Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript


Verastem: The Market Is Ignoring The Progress

Jul 16, 2025, 8:22 AM EDT - 3 months ago

Verastem: The Market Is Ignoring The Progress


U.S. FDA approves Verastem's cancer therapy

May 8, 2025, 12:23 PM EDT - 6 months ago

U.S. FDA approves Verastem's cancer therapy


Verastem Oncology Announces $75 million Private Placement

Apr 25, 2025, 9:00 AM EDT - 6 months ago

Verastem Oncology Announces $75 million Private Placement


Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

Jan 15, 2025, 7:30 AM EST - 10 months ago

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer


Verastem: Planning The PDUFA Run-Up

Jan 3, 2025, 11:56 AM EST - 10 months ago

Verastem: Planning The PDUFA Run-Up


Verastem: BLA Acceptance Puts Key Goals In Sight

Jan 2, 2025, 11:39 AM EST - 10 months ago

Verastem: BLA Acceptance Puts Key Goals In Sight


Verastem: Preparing For Upcoming Catalysts

Nov 27, 2024, 1:28 PM EST - 11 months ago

Verastem: Preparing For Upcoming Catalysts


LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 5:44 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $VSTM Current Share Price: $7.95 Contracts: $VSTM January 15, 2027 $10 Calls Scale in: $3.53- $4.32 Scale out: $5.49-$7.06 Can Easily Capture: 60% ROI Blended DTE: 447 Days | Join Elites here: https://liquidtheta.com
0 · Reply
dl42
dl42 Oct. 25 at 3:22 PM
$VSTM maybe it’s just me being optimistic but this reminds me of TGTX 3-4yrs ago. It just hung around below $10 even w a bunch of upcoming catalysts and then they all started to hit.
0 · Reply
Universaal
Universaal Oct. 25 at 2:15 AM
$VSTM we get another opportunity to load more under 7.90
0 · Reply
NIJO89
NIJO89 Oct. 24 at 11:36 PM
$VSTM Verastem Oncology (VSTM) - Q3 2025 Overview and Key Upcoming Q4 Catalysts: The second-quarter Form 10-Q (filed August 7, 2025) outlined multiple milestones expected in the second half of 2025. While Q3 will primarily reflect early U.S. launch revenue from AVMAPKI (avutometinib + defactinib), expected to land around US $6–8 million, and steady progress in the VS-7375 KRAS G12D program, four major updates remain pending for Q4 2025 that could significantly influence both sentiment and valuation.
0 · Reply
Sdcharger
Sdcharger Oct. 24 at 8:12 PM
$VSTM Short interest at: 10/15. 18.1 million 9/30. 17.5 million The shorts continue to press their bets and the stock continues to lag.
1 · Reply
Marketismanipulated2
Marketismanipulated2 Oct. 24 at 8:06 PM
$VSTM special place in hell for these thieving clock suckers!🤬🤬🤬
0 · Reply
SagehenNed
SagehenNed Oct. 24 at 7:48 PM
$VSTM classic late day VSTM fade.
1 · Reply
Marketismanipulated2
Marketismanipulated2 Oct. 24 at 7:33 PM
$VSTM thieves let it run up or down into the close? Guessing down since they have zero morals.
0 · Reply
Universaal
Universaal Oct. 24 at 4:54 PM
$PRQR few companies i never trust mgmt $PRQR $VSTM bcz these two never gives a fk about their investors I own both
0 · Reply
Universaal
Universaal Oct. 24 at 4:14 PM
$VSTM all I request Dan not to dilute anymore just get some investments from big biotech companies or cut your fking salaries
0 · Reply
MrWaikoloa
MrWaikoloa Oct. 24 at 3:57 PM
$VSTM Heating up niy. Wouldn’t surprise me to see 9 today.
1 · Reply
Universaal
Universaal Oct. 24 at 3:47 PM
$VSTM 😃🤣🤣
0 · Reply
sweddle
sweddle Oct. 24 at 3:45 PM
0 · Reply
Universaal
Universaal Oct. 24 at 3:09 PM
$VSTM added 11k more shares at 7.87, 26k shares holding give me $10 I will get out
1 · Reply
Universaal
Universaal Oct. 24 at 3:02 PM
$VSTM a fkr finally bought 48k shares at 7.78
0 · Reply
PencilNeckGeek
PencilNeckGeek Oct. 24 at 2:44 PM
$VSTM Volume so low one small hedge fund can completely take this wherever they want it to go
1 · Reply
Marketismanipulated2
Marketismanipulated2 Oct. 24 at 2:26 PM
$VSTM shop this company around to highest bidder for crying out loud for the sake of your shareholders.
0 · Reply
PencilNeckGeek
PencilNeckGeek Oct. 24 at 2:22 PM
$VSTM Well looks like they got it pinned down again for the near future
1 · Reply
Universaal
Universaal Oct. 24 at 2:13 PM
$VSTM people not convinced buying more here
0 · Reply
Universaal
Universaal Oct. 24 at 2:02 PM
$VSTM bcz bulls believes these fake people’s comments 😆
0 · Reply
ChesterKaita
ChesterKaita Oct. 24 at 2:00 PM
$VSTM we cure cancer.. what do you do?
0 · Reply
Universaal
Universaal Oct. 24 at 1:59 PM
$VSTM it’s not shorts no one shorting it’s just no fresh buying
0 · Reply